Base de dados : MEDLINE
Pesquisa : D02.241.223.701.350 [Categoria DeCS]
Referências encontradas : 280 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 280 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28770976
[Au] Autor:Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
[Ad] Endereço:Centre for Pain Research, University of Bath, Claverton Down, Bath, UK.
[Ti] Título:Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
[So] Source:Cochrane Database Syst Rev;8:CD012537, 2017 08 02.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization guidelines for pharmacological treatments for children's persisting pain acknowledge that pain in children is a major public health concern of high significance in most parts of the world. While in the past pain was largely dismissed and was frequently left untreated, views on children's pain have changed over time, and relief of pain is now seen as important.We designed a suite of seven reviews on chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs, non-steroidal anti-inflammatory drugs, opioids, and paracetamol) in order to review the evidence for children's pain utilising pharmacological interventions.As the leading cause of morbidity in the world today, chronic disease (and its associated pain) is a major health concern. Chronic pain (that is pain lasting three months or longer) can arise in the paediatric population in a variety of pathophysiological classifications (nociceptive, neuropathic, or idiopathic) from genetic conditions, nerve damage pain, chronic musculoskeletal pain, and chronic abdominal pain, as well as for other unknown reasons.Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and for their anti-inflammation properties. They are commonly used within paediatric pain management. Non-steroidal anti-inflammatory drugs are currently licensed for use in Western countries, however they are not approved for infants under three months old. The main adverse effects include renal impairment and gastrointestinal issues. Common side effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness, and abdominal pain. OBJECTIVES: To assess the analgesic efficacy and adverse events of NSAIDs used to treat chronic non-cancer pain in children and adolescents aged between birth and 17 years, in any setting. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online, MEDLINE via Ovid, and Embase via Ovid from inception to 6 September 2016. We also searched the reference lists of retrieved studies and reviews, as well as online clinical trial registries. SELECTION CRITERIA: Randomised controlled trials, with or without blinding, of any dose and any route, treating chronic non-cancer pain in children and adolescents, comparing any NSAID with placebo or an active comparator. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for eligibility. We planned to use dichotomous data to calculate risk ratio and number needed to treat for one additional event, using standard methods. We assessed GRADE and created three 'Summary of findings' tables. MAIN RESULTS: We included seven studies with a total of 1074 participants (aged 2 to 18 years) with chronic juvenile polyarthritis or chronic juvenile rheumatoid arthritis. All seven studies compared an NSAID with an active comparator. None of the studies were placebo controlled. No two studies investigated the same type of NSAID compared with another. We were unable to perform a meta-analysis.Risk of bias varied. For randomisation and allocation concealment, one study was low risk and six studies were unclear risk. For blinding of participants and personnel, three studies were low risk and four studies were unclear to high risk. For blinding of outcome assessors, all studies were unclear risk. For attrition, four studies were low risk and three studies were unclear risk. For selective reporting, four studies were low risk, two studies were unclear risk, and one study was high risk. For size, three studies were unclear risk and four studies were high risk. For other potential sources of bias, seven studies were low risk. Primary outcomesThree studies reported participant-reported pain relief of 30% or greater, showing no statistically significant difference in pain scores between meloxicam and naproxen, celecoxib and naproxen, or rofecoxib and naproxen (P > 0.05) (low-quality evidence).One study reported participant-reported pain relief of 50% or greater, showing no statistically significant difference in pain scores between low-dose meloxicam (0.125 mg/kg) and high-dose meloxicam (0.25 mg/kg) when compared to naproxen 10 mg/kg (P > 0.05) (low-quality evidence).One study reported Patient Global Impression of Change, showing 'very much improved' in 85% of ibuprofen and 90% of aspirin participants (low-quality evidence). Secondary outcomesAll seven studies reported adverse events. Participants reporting an adverse event (one or more per person) by drug were: aspirin 85/202; fenoprofen 28/49; ibuprofen 40/45; indomethacin 9/30; ketoprofen 9/30; meloxicam 18/47; naproxen 44/202; and rofecoxib 47/209 (very low-quality evidence).All seven studies reported withdrawals due to adverse events. Participants withdrawn due to an adverse event by drug were: aspirin 16/120; celecoxib 10/159; fenoprofen 0/49; ibuprofen 0/45; indomethacin 0/30; ketoprofen 0/30; meloxicam 10/147; naproxen 17/285; and rofecoxib 3/209 (very low-quality evidence).All seven studies reported serious adverse events. Participants experiencing a serious adverse event by drug were: aspirin 13/120; celecoxib 5/159; fenoprofen 0/79; ketoprofen 0/30; ibuprofen 4/45; indomethacin 0/30; meloxicam 11/147; naproxen 10/285; and rofecoxib 0/209 (very low-quality evidence).There were few or no data for our remaining secondary outcomes: Carer Global Impression of Change; requirement for rescue analgesia; sleep duration and quality; acceptability of treatment; physical functioning as defined by validated scales; and quality of life as defined by validated scales (very low-quality evidence).We rated the overall quality of the evidence (GRADE rating) for our primary and secondary outcomes as very low because there were limited data from studies and no opportunity for a meta-analysis. AUTHORS' CONCLUSIONS: We identified only a small number of studies, with insufficient data for analysis.As we could undertake no meta-analysis, we are unable to comment about efficacy or harm from the use of NSAIDs to treat chronic non-cancer pain in children and adolescents. Similarly, we cannot comment on our remaining secondary outcomes: Carer Global Impression of Change; requirement for rescue analgesia; sleep duration and quality; acceptability of treatment; physical functioning; and quality of life.We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Artrite Juvenil/tratamento farmacológico
Artrite Reumatoide/tratamento farmacológico
Dor Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Anti-Inflamatórios não Esteroides/efeitos adversos
Aspirina/efeitos adversos
Aspirina/uso terapêutico
Celecoxib/efeitos adversos
Celecoxib/uso terapêutico
Criança
Pré-Escolar
Doença Crônica
Fenoprofeno/efeitos adversos
Fenoprofeno/uso terapêutico
Seres Humanos
Ibuprofeno/efeitos adversos
Ibuprofeno/uso terapêutico
Lactonas/efeitos adversos
Lactonas/uso terapêutico
Metoxaleno/efeitos adversos
Metoxaleno/uso terapêutico
Naproxeno/efeitos adversos
Naproxeno/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Sulfonas/efeitos adversos
Sulfonas/uso terapêutico
Tiazinas/efeitos adversos
Tiazinas/uso terapêutico
Tiazóis/efeitos adversos
Tiazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Lactones); 0 (Sulfones); 0 (Thiazines); 0 (Thiazoles); 0QTW8Z7MCR (rofecoxib); 57Y76R9ATQ (Naproxen); JCX84Q7J1L (Celecoxib); R16CO5Y76E (Aspirin); RA33EAC7KY (Fenoprofen); U4VJ29L7BQ (Methoxsalen); VG2QF83CGL (meloxicam); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012537.pub2


  2 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27928710
[Au] Autor:Kameshwar VH; R KJ; Priya BS; Swamy SN
[Ad] Endereço:Department of Biotechnology, JSS Science and Technology University, Mysuru, 570006, India.
[Ti] Título:Synthesis, characterization and bioactivity studies of novel 1,3,4-oxadiazole small molecule that targets basic phospholipase A from Vipera russelli.
[So] Source:Mol Cell Biochem;426(1-2):161-175, 2017 Feb.
[Is] ISSN:1573-4919
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Secretory phospholipase A (sPLA ) is a key enzyme participating in the inflammatory cascade followed by the action of cyclooxygenase-2 and lipoxygenases. Therefore, inhibitors of sPLA could be used as potent anti-inflammatory agents to treat the early phase of inflammation. In this study, we have prepared the fenoprofen and ibuprofen analogs containing 1,3,4-oxadiazole nucleus and tested against Vipera russelli venom's basic sPLA (VRV-PL-VIIIa). Among the tested ligands 5(a-t),2-(2-chlorophenyl)-5-(1-(4-phenoxyphenyl) ethyl)-1,3,4-oxadiazole (5m) inhibited the catalytic activity of VRV-PL-VIIIa with an IC value of 11.52 µM. Biophysical studies revealed that the 5m quenches the intrinsic fluorescence of VRV-PL-VIIIa, in a concentration dependent manner. Also, the compound 5m affected VRV-PL-VIIIa conformation, which was observed by circular dichroism spectra that recorded the prominent shift in the α-helix peak and the random coil formation of VRV-PL-VIIIa. Further, molecular docking analysis revealed that the compound 5m possess strong hydrophobic interactions at catalytic triad region of the VRV-PL-VIIIa. Evident to in vitro and in silico studies, 5m strongly inhibited the hemolysis of red blood cells. Our in vivo pharmacological studies revealed that the compound 5m inhibited the edematogenic activity of VRV-PL-VIIIa in mouse foot pad. Additionally, the 5m inhibited VRV-PL-VIIIa-induced myotoxicity and lung hemorrhage in mice. Overall, our ADMET results depicted that 5m possess better druggable property. Thus, this study explored the new fenoprofen and ibuprofen analog 5m as the lead-structure that serves as an anti-inflammatory agent.
[Mh] Termos MeSH primário: Inibidores Enzimáticos
Fenoprofeno
Fosfolipases A2 do Grupo II
Ibuprofeno
Oxidiazóis
[Mh] Termos MeSH secundário: Animais
Inibidores Enzimáticos/síntese química
Inibidores Enzimáticos/química
Inibidores Enzimáticos/farmacologia
Fenoprofeno/análogos & derivados
Fenoprofeno/síntese química
Fenoprofeno/química
Fenoprofeno/farmacologia
Fosfolipases A2 do Grupo II/antagonistas & inibidores
Fosfolipases A2 do Grupo II/química
Fosfolipases A2 do Grupo II/toxicidade
Hemólise/efeitos dos fármacos
Ibuprofeno/análogos & derivados
Ibuprofeno/síntese química
Ibuprofeno/química
Ibuprofeno/farmacologia
Masculino
Camundongos
Simulação de Acoplamento Molecular
Oxidiazóis/síntese química
Oxidiazóis/química
Oxidiazóis/farmacologia
Estrutura Secundária de Proteína
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Oxadiazoles); 20O2F20OUR (1,3,4-oxadiazole); EC 3.1.1.4 (Group II Phospholipases A2); EC 3.1.4 (VRV-PL-VIIIa phospholipase A2, Vipera russelli); RA33EAC7KY (Fenoprofen); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161209
[St] Status:MEDLINE
[do] DOI:10.1007/s11010-016-2888-6


  3 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27853832
[Au] Autor:Montero-Melendez T; Forfar RA; Cook JM; Jerman JC; Taylor DL; Perretti M
[Ad] Endereço:The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. t.monteromelendez@qmul.ac.uk.
[Ti] Título:Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3.
[So] Source:Cell Mol Life Sci;74(7):1335-1345, 2017 Apr.
[Is] ISSN:1420-9071
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The efficiency of drug research and development has paradoxically declined over the last decades despite major scientific and technological advances, promoting new cost-effective strategies such as drug repositioning by systematic screening for new actions of known drugs. Here, we performed a screening for positive allosteric modulators (PAMs) at melanocortin (MC) receptors. The non-steroidal anti-inflammatory drug fenoprofen, but not the similar compound ibuprofen, presented PAM activity at MC , MC , and MC receptors. In a model of inflammatory arthritis, fenoprofen afforded potent inhibition while ibuprofen was nearly inactive. Fenoprofen presented anti-arthritic actions on cartilage integrity and synovitis, effects markedly attenuated in Mc3r-/- mice. Fenoprofen displayed pro-resolving properties promoting macrophage phagocytosis and efferocytosis, independently of cyclooxygenase inhibition. In conclusion, combining repositioning with advances in G-protein coupled receptor biology (allosterism) may lead to potential new therapeutics. In addition, MC PAMs emerged as a viable approach to the development of innovative therapeutics for joint diseases.
[Mh] Termos MeSH primário: Regulação Alostérica/efeitos dos fármacos
Anti-Inflamatórios não Esteroides/farmacologia
Reposicionamento de Medicamentos
Fenoprofeno/farmacologia
Receptor Tipo 3 de Melanocortina/metabolismo
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/uso terapêutico
Artrite/tratamento farmacológico
Artrite/etiologia
Células CHO
Cricetinae
Cricetulus
Modelos Animais de Doenças
Fenoprofeno/uso terapêutico
Articulações/metabolismo
Articulações/patologia
Macrófagos/citologia
Macrófagos/imunologia
Macrófagos/metabolismo
Masculino
Melanocortinas/análise
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Peritonite/induzido quimicamente
Peritonite/tratamento farmacológico
Peritonite/patologia
Fagocitose/efeitos dos fármacos
Prostaglandina-Endoperóxido Sintases/química
Prostaglandina-Endoperóxido Sintases/metabolismo
Receptor Tipo 3 de Melanocortina/química
Receptor Tipo 3 de Melanocortina/deficiência
Receptor Tipo 3 de Melanocortina/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Melanocortins); 0 (Receptor, Melanocortin, Type 3); EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases); RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161118
[St] Status:MEDLINE
[do] DOI:10.1007/s00018-016-2419-3


  4 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26037509
[Au] Autor:Wang N; Wang F; Meng Y; Yang GH; Chen JW; Wang JX
[Ad] Endereço:Department of Emergency, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
[Ti] Título:Albumin Supplement Affects the Metabolism and Metabolism-Related Drug-Drug Interaction of Fenoprofen Enantiomers.
[So] Source:Chirality;27(7):436-40, 2015 Jul.
[Is] ISSN:1520-636X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The influence of albumin towards the metabolism behavior of fenoprofen enantiomers and relevant drug-drug interaction was investigated in the present study. The metabolic behavior of fenoprofen enantiomers was compared in a phase II metabolic incubation system with and without bovine serum albumin (BSA). BSA supplement increased the binding affinity parameter (Km) of (R)-fenoprofen towards human liver microsomes (HLMs) from 148.3 to 214.4 µM. In contrast, BSA supplement decreased the Km of (S)-fenoprofen towards HLMs from 218.2 to 123.5 µM. For maximum reaction velocity (Vmax), the addition of BSA increased the Vmax of (R)-fenoprofen from 1.3 to 1.6 nmol/min/mg protein. In the contrast, BSA supplement decreased the Vmax value from 3.3 to 1.5 nmol/min/mg protein. Andrographolide-fenoprofen interaction was used as an example to investigate the influence of BSA supplement towards fenoprofen-relevant drug-drug interaction. The addition of 0.2% BSA in the incubation system significantly decreased the inhibition potential of andrographolide towards (R)-fenoprofen metabolism (P < 0.001). Different from (R)-fenoprofen, the addition of BSA significantly increased the inhibition potential of andrographolide towards the metabolism of (S)-fenoprofen. BSA supplement also changed the inhibition kinetic type and parameter of andrographolide towards the metabolism of (S)-fenoprofen. In conclusion, albumin supplement changes the metabolic behavior of fenoprofen enantiomers and the fenoprofen-andrographolide interaction.
[Mh] Termos MeSH primário: Interações Medicamentosas
Fenoprofeno/química
Fenoprofeno/farmacocinética
Soroalbumina Bovina/metabolismo
[Mh] Termos MeSH secundário: Diterpenos/metabolismo
Diterpenos/farmacocinética
Fenoprofeno/metabolismo
Seres Humanos
Cinética
Microssomos Hepáticos/efeitos dos fármacos
Microssomos Hepáticos/metabolismo
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Diterpenes); 27432CM55Q (Serum Albumin, Bovine); 410105JHGR (andrographolide); RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150604
[St] Status:MEDLINE
[do] DOI:10.1002/chir.22462


  5 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25554116
[Au] Autor:Majumder J; Yedoti P; Dastidar P
[Ad] Endereço:Department of Organic Chemistry, Indian Association for the Cultivation of Science, 2A & 2B Raja S. C. Mullick Road, Kolkata 700032, India. ocpd@iacs.res.in.
[Ti] Título:A supramolecular topical gel derived from a non-steroidal anti-inflammatory drug, fenoprofen, is capable of treating skin inflammation in mice.
[So] Source:Org Biomol Chem;13(8):2300-9, 2015 Feb 28.
[Is] ISSN:1477-0539
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A new series of bioconjugates derived from a non-steroidal anti-inflammatory drug (NSAID), namely fenoprofen, has been synthesised by amidation with various biogenic molecules such as ß-alanine, aminocaproic acid and tyramine with the aim of converting the NSAID into a supramolecular gelator for plausible biomedical applications. One such bioconjugate (2) showed gelation ability with methylsalicylate (MS) and 1% menthol in methyl salicylate (MMS) solvents. These gels were characterized by table top rheology, high resolution-transmission electron microscopy (HR-TEM) and dynamic rheology. Gelator 2 was found to be biostable both in proteolytic enzymes and in blood serum of BALB/c mouse under physiological conditions. It was also found to be biocompatible, as revealed by the methyl thiazolyldiphenyl tetrazolium bromide (MTT) assay in mouse macrophage RAW 264.7 and mouse myoblast C2C12 cells. The anti-inflammatory response (prostaglandin E2 assay, denoted PGE2 assay) of 2 was comparable to that of the parent drug fenoprofen calcium salt. Finally, a topical gel formulation of 2 displayed in vivo self-delivery application in treating imiquimod (IMQ) induced skin inflammation in BALB/c mice.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/administração & dosagem
Anti-Inflamatórios não Esteroides/uso terapêutico
Fenoprofeno/administração & dosagem
Fenoprofeno/uso terapêutico
Inflamação/tratamento farmacológico
Dermatopatias/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Anti-Inflamatórios não Esteroides/síntese química
Anti-Inflamatórios não Esteroides/farmacologia
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Fenoprofeno/química
Fenoprofeno/farmacologia
Géis
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Estrutura Molecular
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Gels); RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150211
[Lr] Data última revisão:
150211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150103
[St] Status:MEDLINE
[do] DOI:10.1039/c4ob02344g


  6 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25050353
[Au] Autor:Agotegaray M; Gumilar F; Boeris M; Toso R; Minetti A
[Ad] Endereço:INQUISUR, Departamento de Química, Universidad Nacional del Sur, Avenida Alem 1253, B8000CPB Bahía Blanca, Argentina.
[Ti] Título:Enhanced analgesic properties and reduced ulcerogenic effect of a mononuclear copper(II) complex with fenoprofen in comparison to the parent drug: promising insights in the treatment of chronic inflammatory diseases.
[So] Source:Biomed Res Int;2014:505987, 2014.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Analgesic and ulcerogenic properties have been studied for the copper(II) coordination complex of the nonsteroidal anti-inflammatory drug Fenoprofen and imidazole [Cu(fen)2(im)2] (Cu: copper(II) ion; fen: fenoprofenate anion from Fenoprofen, im: imidazole). A therapeutic dose of 28 mg/kg was tested for [Cu(fen)2(im)2] and 21 mg/kg was employed for Fenoprofen calcium, administered by oral gavage in female mice to compare the therapeutic properties of the new entity. The acetic acid induced writhing test was employed to study visceral pain. The percentage of inhibition in writhing and stretching was 78.9% and 46.2% for the [Cu(fen)2(im)2] and Fenoprofen calcium, respectively. This result indicates that the complex could be more effective in diminishing visceral pain. The formalin test was evaluated to study the impact of the drugs over nociceptive and inflammatory pain. The complex is a more potent analgesic on inflammatory pain than the parent drug. Ulcerogenic effects were evaluated using a model of gastric lesions induced by hypothermic-restraint stress. Fenoprofen calcium salt caused an ulcer index of about 79 mm(2) while the one caused by [Cu(fen)2(im)2] was 22 mm(2). The complex diminished the development of gastric mucosal ulcers in comparison to the uncomplexed drug. Possible mechanisms of action related to both therapeutic properties have been discussed.
[Mh] Termos MeSH primário: Analgésicos/uso terapêutico
Complexos de Coordenação/uso terapêutico
Cobre/uso terapêutico
Fenoprofeno/uso terapêutico
Doenças Inflamatórias Intestinais/tratamento farmacológico
Úlcera Gástrica/tratamento farmacológico
[Mh] Termos MeSH secundário: Analgésicos/química
Analgésicos/farmacologia
Animais
Doença Crônica
Complexos de Coordenação/química
Complexos de Coordenação/farmacologia
Cobre/química
Cobre/farmacologia
Feminino
Fenoprofeno/química
Fenoprofeno/farmacologia
Doenças Inflamatórias Intestinais/patologia
Camundongos
Úlcera Gástrica/patologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics); 0 (Coordination Complexes); 789U1901C5 (Copper); RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140723
[St] Status:MEDLINE
[do] DOI:10.1155/2014/505987


  7 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24709160
[Au] Autor:Yin JB; Cui GB; Mi MS; Du YX; Wu SX; Li YQ; Wang W
[Ad] Endereço:Unit for Evidence Based Medicine, Department of Human Anatomy & K.K. Leung Brain Research Centre, Preclinical School of Medicine, Fourth Military Medical University, Xi'an, PR China.
[Ti] Título:Local infiltration analgesia for postoperative pain after hip arthroplasty: a systematic review and meta-analysis.
[So] Source:J Pain;15(8):781-99, 2014 Aug.
[Is] ISSN:1528-8447
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Postoperative pain after hip arthroplasty (HA) is very common and severe. Currently, use of routine analgesic methods is often accompanied by adverse events (AEs). Local infiltration analgesia (LIA) for controlling pain has been a therapeutic option in many surgical procedures. However, its analgesic efficacy in HA and its safety remain unclear. Data from 9 randomized controlled trials, involving 760 participants, comparing the effect of LIA with that of placebo infiltration or no infiltration on patients undergoing HA were retrieved from an electronic database, and the pain scores, analgesic consumption, and AEs were analyzed. Effects were summarized using weighted mean differences, standardized mean differences, or odds ratio with fixed or random effect models. There was strong evidence of an association between LIA and reduced pain scores at 4 hours at rest (P < .00001) and with motion (P < .00001), 6 hours with motion (P = .02), and 24 hours at rest (P = .01), and decreased analgesic consumption during 0 to 24 hours (P = .001) after HA. These analgesic efficacies for LIA were not accompanied by any increased risk for AEs. However, the current meta-analysis did not reveal any associations between LIA and the reduced pain scores or analgesic consumption at other time points. The results suggest that LIA can be used for controlling pain after HA because of its efficacy in reducing pain scores and thus can reduce analgesic consumption on the first day without increased risk of AEs. PERSPECTIVE: This is the first pooled database meta-analysis to assess the analgesic effects and safety of LIA in controlling pain after HA. The derived information offers direct evidence that LIA can be used for patients undergoing HA because of its ability to reduce pain scores and analgesic consumption without any additional AEs.
[Mh] Termos MeSH primário: Analgesia/métodos
Artroplastia/efeitos adversos
Fenoprofeno/uso terapêutico
Dor Pós-Operatória/tratamento farmacológico
[Mh] Termos MeSH secundário: Vias de Administração de Medicamentos
Quadril/cirurgia
Seres Humanos
Dor Pós-Operatória/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:140802
[Lr] Data última revisão:
140802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140409
[St] Status:MEDLINE


  8 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23540249
[Au] Autor:Abd El-Hady D; Youssef AK
[Ad] Endereço:Chemistry Department, Faculty of Science-North Jeddah, King Abdulaziz University, Saudi Arabia. deiaabdelhady@yahoo.com
[Ti] Título:Hyphenation of ionic liquid albumin glassy carbon biosensor or protein label-free sensor with differential pulse stripping voltammetry for interaction studies of human serum albumin with fenoprofen enantiomers.
[So] Source:Anal Chim Acta;772:68-74, 2013 Apr 15.
[Is] ISSN:1873-4324
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A new biosensor or protein label-free sensor composed of 1-butyl-3-methylimidazolium hexafluorophosphates (BMIMPF6)-human serum albumin (HSA) film on glassy carbon electrode (GCE) was produced. Unfortunately, the native proteins themselves are often unstable in physiological conditions. Here, we introduced conjugation with ionic liquid (IL) such as BMIMPF6 which improved the stability and binding affinity of protein onto GCE. A rapid, simple and reliable method for the chiral discrimination and real time protein binding studies of fenoprofen enantiomers with HSA was developed by hyphenating ionic liquid albumin glassy carbon (ILAGC) biosensor with differential pulse cathodic stripping voltammetry under physiological conditions. The electrochemical behavior of chiral fenoprofen was monitored by cyclic voltammetry, from which large response was obtained from l-fenoprofen. The surface coverage of fenoprofen enantiomers was calculated by double potential-step chronocoulometry. The binding constants of chiral fenoprofen with HSA were estimated to be 3.2×10(5)±0.3 L mol(-1) and 0.8×10(4)±0.4 L mol(-1) for L- and D-fenoprofen, respectively giving acceptable precision (SD ≤ 0.4) and good agreement with the literature values. The competitive interactions of ibuprofen with fenoprofen enantiomers-HSA were studied giving a significant decreasing in the binding degrees of analytes to HSA. The reciprocal competitive experiments indicated that L-fenoprofen replaced D-fenoprofen from HSA. The proposed electrochemical biosensor holds great potential for chiral discrimination and real time binding studies of drugs with protein.
[Mh] Termos MeSH primário: Técnicas Biossensoriais
Fenoprofeno/análise
Imidazóis/química
Líquidos Iônicos/química
Albumina Sérica/química
[Mh] Termos MeSH secundário: Ligação Competitiva
Tampões (Química)
Técnicas Eletroquímicas
Seres Humanos
Ibuprofeno/química
Cinética
Ligação Proteica
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1-butyl-3-methylimidazolium hexafluorophosphate); 0 (Buffers); 0 (Imidazoles); 0 (Ionic Liquids); 0 (Serum Albumin); RA33EAC7KY (Fenoprofen); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1309
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130402
[St] Status:MEDLINE


  9 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:22336801
[Au] Autor:Sivaprasad S; Bunce C; Crosby-Nwaobi R
[Ad] Endereço:Normanby Building, King's CollegeHospital, London, UK. senswathi@aol.com.
[Ti] Título:Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery.
[So] Source:Cochrane Database Syst Rev;(2):CD004239, 2012 Feb 15.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cystoid macular oedema (CMO) is the accumulation of fluid in the central retina (the macula) due to leakage from dilated capillaries. It is the most common cause of poor visual outcome following cataract surgery. The exact cause is unclear. Acute CMO, defined as oedema of less than four months duration, often resolve spontaneously. CMO that persists for four months or more is termed chronic CMO. Different types of non-steroidal anti-inflammatory agents (NSAIDs) are used in the treatment of CMO which may be delivered topically or systemically. OBJECTIVES: To examine the effectiveness of NSAIDs in the treatment of CMO following cataract surgery. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 7), MEDLINE (January 1950 to August 2011), EMBASE (January 1980 to August 2011), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to August 2011), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) (August 2011) and ClinicalTrials.gov (www.clinicaltrials.gov) (August 2011). We searched the reference lists of identified trials. We searched conference abstracts (sessions related to cataract) in The Association for Research in Vision and Ophthalmology (ARVO) 1975 to 2011. We contacted experts in the field and NSAIDs manufacturers for details on published and unpublished trials.There were no language or date restrictions in the search for trials. The electronic databases were last searched on 5 August 2011. SELECTION CRITERIA: We included randomised controlled trials evaluating the effects of NSAIDs in the treatment of CMO following cataract surgery. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data. Since considerable heterogeneity was observed between studies we did not conduct meta-analyses. MAIN RESULTS: Seven trials involving a total of 266 participants were included. Four trials studied the effects of NSAIDs in chronic CMO while the other three examined the effect of NSAIDs in acute CMO. Of the studies examining chronic CMO, one study enrolled 120 participants, but the remainder had 34 or fewer participants. Four different NSAIDs were used and administered in different ways. Indomethacin was used orally and was found to be ineffective for chronic CMO in one trial. Topical fenoprofen appeared effective but not statistically significantly so for chronic CMO in another small trial. Treatment with topical 0.5% ketorolac for chronic CMO was found to be effective in two trials. Three trials examined the effect of topical NSAIDs on acute CMO. The comparisons among these studies were of an NSAID to placebo, prednisolone or another NSAID. The study design differed between the studies in other important aspects thus they could not be combined in a meta-analysis. AUTHORS' CONCLUSIONS: This review found two trials which showed that topical NSAID (0.5% ketorolac tromethamine ophthalmic solution) has a positive effect on chronic CMO and two trials which revealed no significant difference between comparative groups. As such, the effects of NSAIDs in acute and chronic CMO remain unclear and needs further investigation.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Extração de Catarata/efeitos adversos
Edema Macular/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Doença Crônica
Fenoprofeno/uso terapêutico
Seres Humanos
Indometacina/uso terapêutico
Cetorolaco/uso terapêutico
Edema Macular/etiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); RA33EAC7KY (Fenoprofen); XXE1CET956 (Indomethacin); YZI5105V0L (Ketorolac)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120217
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004239.pub3


  10 / 280 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22169772
[Au] Autor:Gumilar F; Agotegaray M; Bras C; Gandini NA; Minetti A; Quinzani O
[Ad] Endereço:Laboratorio de Toxicología, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, B8000CPB, Bahía Blanca, Argentina. fgumilar@criba.edu.ar
[Ti] Título:Anti-nociceptive activity and toxicity evaluation of Cu(II)-fenoprofenate complexes in mice.
[So] Source:Eur J Pharmacol;675(1-3):32-9, 2012 Jan 30.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The proposed curative properties of copper(II)-non-steroidal anti-inflammatory drugs (NSAIDs) have led to the development of numerous copper(II)-NSAID complexes with enhanced anti-inflammatory activity. In this work, the antinociceptive and toxic effects of two new coordination complexes: Cu2(fen)4(caf)2 [fen: fenoprofenate anion; caf: caffeine] and Cu2(fen)4(dmf)2 [dmf: N-N'-dimethylformamide] were evaluated in mice. The antinociceptive effect was evaluated with two models: acetic acid-induced writhing response and formalin test. For the sub-acute exposure, the complexes were added to the diet at different doses for 28days. Behavioral and functional nervous system parameters in a functional observational battery were assessed. Also, hematological, biochemical and histopathological studies were performed. Cu2(fen)4(caf)2 and Cu2(fen)4(dmf)2 significantly decreased the acetic acid-induced writhing response and the licking time on the late phase in the formalin test with respect to the control and fenoprofen salt groups. The sub-acute exposure to Cu2(fen)4(caf)2 complex increased the motor activity, the number of rearings and the arousal with respect to the control and fenoprofen salt groups. These impaired parameters in mice exposed to Cu2(fen)4(caf)2 can be attributable to the presence of caffeine as stimulating agent. On the other hand, all exposed groups decreased the urine pools in the functional observational battery and increased the plasmatic urea. These effects could be due to the decrease in the glomerular filtration caused by NSAIDs. In conclusion, both complexes Cu2(fen)4(dmf)2 and Cu2(fen)4(caf)2 were more potent antinociceptive agents than fenoprofen salt. Sub-acute exposure to different doses of these complexes did not produce significant changes in the parameters that evaluate toxicity.
[Mh] Termos MeSH primário: Dor Abdominal/tratamento farmacológico
Analgésicos/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Complexos de Coordenação/uso terapêutico
Fenoprofeno/uso terapêutico
Inflamação/tratamento farmacológico
[Mh] Termos MeSH secundário: Dor Abdominal/sangue
Dor Abdominal/prevenção & controle
Dor Abdominal/urina
Analgésicos/administração & dosagem
Analgésicos/efeitos adversos
Analgésicos/química
Animais
Anti-Inflamatórios não Esteroides/administração & dosagem
Anti-Inflamatórios não Esteroides/efeitos adversos
Anti-Inflamatórios não Esteroides/química
Nível de Alerta/efeitos dos fármacos
Cafeína/administração & dosagem
Cafeína/efeitos adversos
Cafeína/química
Cafeína/uso terapêutico
Estimulantes do Sistema Nervoso Central/administração & dosagem
Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/química
Estimulantes do Sistema Nervoso Central/uso terapêutico
Complexos de Coordenação/administração & dosagem
Complexos de Coordenação/efeitos adversos
Complexos de Coordenação/química
Cobre/administração & dosagem
Cobre/efeitos adversos
Cobre/química
Dimetilformamida/administração & dosagem
Dimetilformamida/química
Relação Dose-Resposta a Droga
Feminino
Fenoprofeno/administração & dosagem
Fenoprofeno/efeitos adversos
Fenoprofeno/química
Insuficiência Hepática/induzido quimicamente
Inflamação/sangue
Inflamação/prevenção & controle
Inflamação/urina
Camundongos
Medição da Dor
Distribuição Aleatória
Insuficiência Renal/induzido quimicamente
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Central Nervous System Stimulants); 0 (Coordination Complexes); 3G6A5W338E (Caffeine); 789U1901C5 (Copper); 8696NH0Y2X (Dimethylformamide); RA33EAC7KY (Fenoprofen)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111216
[St] Status:MEDLINE
[do] DOI:10.1016/j.ejphar.2011.11.049



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde